SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently under intense selling pressure as investors weigh concerns about potential AI market competition against its long-term enterprise software growth. The community remains deeply divided, with some traders citing technical overextension and 'FUD' around the stock's valuation, while many long-term bulls are aggressively 'buying the dip' in anticipation of a rebound ahead of the next earnings report.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing a brutal sell-off as investors grapple with 'SaaSpocalypse' fears, triggered by concerns that AI agents and large language models like Anthropic's could commoditize enterprise software and erode traditional subscription-based moats. While the stock has hit fresh 52-week lows and faces negative sentiment from recent analyst downgrades, the community remains deeply polarized between those panic-selling to avoid further downside and contrarian 'bottom-fishers' who argue the company's enterprise integration and AI-enabled product updates are being unfairly discounted.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is capturing significant market attention following a massive expansion of its long-term cloud infrastructure deal with Meta, now valued at over $35 billion, and a new multi-year partnership with Anthropic to power its Claude AI models. While the community is actively debating the implications of the company's $3.5 billion convertible note offering and its aggressive debt-fueled growth strategy, bullish sentiment remains focused on CoreWeave's cementing of its position as a primary infrastructure provider for the world's leading AI model developers.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and downward pressure as the market reacts to a major workforce restructuring involving thousands of layoffs, aimed at reallocating capital toward AI infrastructure and cloud expansion. Despite community debate over whether the company's aggressive AI push and massive debt load justify the current valuation, investors are closely watching institutional financing moves and data center development as key catalysts for a potential long-term turnaround.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing significant volatility following the release of preliminary first-quarter financial results that indicated record shipments and manufacturing output, sparking intense debate among investors about the company's ability to scale production. While bulls are highlighting manufacturing improvements and a substantial commercial backlog as catalysts for a recovery, skeptics remain cautious, citing a history of missed guidance and concerns over product performance that continue to weigh on market trust.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors weigh the stock's recent volatility against an upcoming FDA PDUFA decision for its lead candidate, RP1, in refractory melanoma. Community sentiment is deeply divided, with discussions centered on whether new data and a shifting FDA regulatory landscape will lead to a reversal of the previous Complete Response Letter, or if the stock faces further downside.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors rally behind the company's strong AI infrastructure positioning, with community discussion fueled by reports of potential acquisition talks with AI21 Labs and a wave of positive analyst sentiment. Market participants are actively debating the stock's breakout potential as it retests all-time highs, with significant attention paid to its strategic partnerships and institutional accumulation.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors digest news that the company expects to be completely sold out of its capacity through 2028, fueling intense debate over whether its current valuation reflects a fundamental AI infrastructure bottleneck or a speculative bubble. While bulls are pointing to the critical role of photonics in scaling data centers and sustaining NVIDIA-backed demand, bears are aggressively highlighting the stock's massive year-over-year gains, concerns over high price-to-earnings multiples, and the inherent risks of cyclical hardware spending.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp (CRML) is seeing heightened investor attention as market participants speculate on the strategic value of its Greenland-based Tanbreez project amid broader geopolitical shifts and commodity supply chain concerns. Community discussions are heavily focused on the anticipation of updated project studies and potential catalysts related to U.S. critical mineral self-sufficiency.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is witnessing extreme volatility and a parabolic rally driven by bullish sentiment around AI-induced memory demand and a flurry of aggressive price target hikes from analysts. While retail investors remain heavily focused on potential stock split catalysts ahead of upcoming earnings, others are warning of a crowded trade and potential rug pull as market makers navigate high call volume and overextended valuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The workforce reduction will be “substantially completed” by Feb. 13.&nbsp;</li><li>As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter.</li><li>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move.</li></ul>Werewolf Therapeutics, Inc. (HOWL) has decided to reduce its workforce by 64% as it seeks to lower its operating costs, the company said in a filing with the Securities and Exchange Commission on Friday.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001785530/000119312526051455/d110809d8k.htm">said</a> that the decision was approved by its Board of Directors on Feb. 9, and the workforce reduction will be “substantially completed” by Feb. 13.As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter. The amount includes employee separation benefits, including severance and related benefits.Shares of the company rose over 4% after hours after closing down 1% in the regular trading session.<h2 class="st-heading-2">CFO &amp; CMO Exits</h2>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move and are entitled to severance benefits including an amount equal to nine months of their base salary, Werewolf Therapeutics said. &nbsp;However, both the executives will assist in aiding a transition of their responsibilities from time to time for up to six months. &nbsp;The company also said on Friday that it is evaluating alternatives such as strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs. It sought to raise capital in the fourth quarter of 2025 as well as the first quarter of 2026 to fund operations and has engaged in investor discussions regarding pipeline and financing, it added.However, the company said on Friday that there is no guarantee that any transaction would occur.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HOWL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/HOWL">HOWL stock</a> has dropped 57% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slumps-after-fda-declines-approval-for-inherited-disorder-drug/cZRd2YMR4tK">Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Werewolf Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 

Equity

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 


Luke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average...

Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...

Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 17,858 shares of the company's stock in a transaction dated Friday, December 12th. The shares were sold at an...

Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Current Price	$0.888
Prev Close	$0.8984
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$0.7437
Beta	1.69
Avg. Volume	376,340.37
PE Ratio	-0.67

52-Week High	$2.38
52-Week Low	$0.5301
Market Capitalization	$43.66M
EPS (Annual)	-$1.33
Price to Book	1.76
Revenue Per Employee	$0.00

HOWL
Werewolf Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HOWL News

HOWLWerewolf Therapeutics Inc